Form 4: Alnylam Pharmaceuticals CSO Kevin Fitzgerald Reports Stock Transactions

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reports the acquisition and disposition of company stock and stock options.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, filed a Form 4 detailing stock transactions.
• On March 3, 2025, Fitzgerald acquired 3,871 shares of common stock through restricted stock units (RSUs) at $0.00.
• Fitzgerald also sold multiple blocks of common stock on March 3 and March 4, 2025, at prices ranging from $238.93 to $248.36 per share.
• These sales totaled 2,231 shares.
• These sales were executed to cover minimum statutory tax withholding obligations and pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Fitzgerald also acquired 7,819 stock options with an exercise price of $243.53 on March 3, 2025, exercisable starting March 3, 2035.
• Following these transactions, Fitzgerald directly owns 13,501 shares of common stock and indirectly owns 537 shares through a managed account and 7,819 stock options.
• The reporting person also indirectly owns 537 shares by Managed Account.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and do not indicate any significant positive or negative developments for the company.

Positives

• The acquisition of RSUs and stock options indicates confidence in the company's future performance.
• The transactions are partly driven by vesting of stock options and RSUs, which is a regular occurrence for executives.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it is a common practice.

Risks

• Executive stock sales could create short-term downward pressure on the stock price.
• Changes in executive compensation structures or vesting schedules could impact future transactions.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing vesting of RSUs and stock options suggests continued transactions in the future.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical industry where equity compensation is a significant part of overall remuneration. These transactions are closely monitored by investors for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies.
• The vesting schedules and trading plans employed by Alnylam are consistent with industry best practices for aligning executive incentives with shareholder value.

Stakeholder Impact

• Shareholders may be interested in the executive's transactions as an indicator of confidence in the company.
• Employees may be impacted by the overall compensation structure and equity ownership within the company.

Next Steps

• Continued monitoring of executive stock transactions for further insights into management's perspective.
• Tracking the vesting schedule of RSUs and stock options to anticipate future transactions.

Key Dates